$128.800
-0.902 (-0.70%)收盤時
RVTY 資訊
RVTY 事件
Company to Divest Immunodiagnostics Business in China
The company recently entered into a definitive agreement to divest its Immunodiagnostics business in China, which represented approximately 6% of the company's total revenue in fiscal year 2025. The transaction is expected to close by the end of 2027, subject to customary closing conditions and regulatory approvals. The company is providing second quarter 2026 financial results on a reported and pro forma basis; forward-looking guidance is provided on a pro forma basis only and excludes China IDX.
Revvity Reports Q2 Revenue of $730M
Reports Q2 revenue $730M, consensus $703.18M. "Revvity delivered a strong second quarter, with results above our expectations and encouraging signs of increased demand across our customer base," said Prahlad Singh, president and chief executive officer of Revvity. "As we enter the second half of the year, given the clear momentum in our end markets, we are utilizing a portion of recently received tariff refunds to increase investments across the business, capitalize on emerging opportunities, and support future growth."
FY26 Revenue Outlook Raised to $2.83B-$2.86B
FY26 consensus $5.25. Raises FY26 revenue view to $2.83B-$2.86B from $2.81B-$2.84B, consensus $2.83B.
Revvity Signals Software Joins Anthropic Directory
Revvity announced that its Revvity Signals Software business has joined Anthropic's directory for Model Context Protocol connectors, enabling scientists to access Signals AI capabilities and connected R&D knowledge through Claude. Through the Signals MCP connector, Claude can securely access information through Signals' intelligence layer, helping researchers search, understand and act on complex R&D data using natural language. "Signals AI was designed to help scientists transform connected R&D data into understanding, decisions and action," said Kevin Willoe, president of Revvity Signals Software. "By joining Anthropic's MCP ecosystem, we're extending the reach of our Signals AI beyond our Signals One platform and enabling researchers to combine Claude's reasoning capabilities with the governed data, ontology-driven scientific context and trusted knowledge managed across the entire Revvity Signals offering."
Bio Techne Gains 11.45% to $70.33
Notable gainers among liquid option names this morning include Bio Techne (TECH) $70.33 +11.45, Sandisk Corporation (SNDK) $2133.50 +219.04, Micron (MU) $1148.07 +99.56, PerkinElmer Inc (RVTY) $112.91 +7.28, and Xylem (XYL) $117.97 +5.93.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。